Abstract: An herbal preparation comprised of sage, thyme and cumin is found to relieve the symptoms of inflammation and smooth muscle contraction. The preparation preferably comprises sage, thyme and cumin in the proportions 0.50, 0.43 and 0.07 respectively. The symptoms of menstrual cramps and asthma are relieved by administration of the preparation.

Abstract: This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological disorder such as endometriosis, uterine fibroids, postoperative peritoneal adhesions, dysfunctional bleeding (metrorrhagia, menorrhagia) and dysmenorrhea; b) for the prevention of gynecological disorders such as postoperative, peritoneal adhesions, dysfunctional uterine bleeding (metrorrhagia, menorrhagia) and dysmenorrhea; and c) a method of treatment and prevention of the above mentioned disorders in a female, preferably in a human female, in need of treatment or prevention of one or more of these disorders, with an effective amount of a mesoprogestin. Mesoprogestins are defined as compounds possessing both agonistic and antagonistic activities at the progesterone receptor (PR) in vivo.

Abstract: A therapeutic agent for treating polycystic ovary syndrome (PCOS), which exhibits few, if any, side effects, is effective at inducing ovulation, and is safely available for not only females who desire to bear children, but also for unmarried or young females. A therapeutic agent for polycystic ovary syndrome (PCOS) in which an extract of mushrooms is contained as the active ingredient thereof is used.

Abstract: A method of using an herbal extract of the a mixture of: Herba Scutellaria barbata, Radix Sophora subprostratae, Radix Anemarrhena, Semen Glycine sojae, Radix Glycyrrhiza, Rhizoma Rhei, Fructus Tritici levis, Radix Astragali, Radix Rehmania, Fructus Ligustri lucidi, Semen Zyziphi spinosa, Plumula Nelumbinis, Poria cocas, Rhizoma Alismatis, Cortex Moutan radicis, Fructus Corni, Radix Achyranthis, Concha Ostrea, Radix Aspargi, Radix Pueraria, Radix Atractylodis macrocephala and Herba Epimedium, for the treatment of hot flashes associated with menopause is disclosed herein.

Abstract: The present invention is directed to the controlled delivery of gonadotropin-releasing hormone (GnRH) agonists, preferably from a polymeric material that is implanted in the body. More specifically, the present invention relates to compositions comprised of a GnRH agonist, preferably histrelin, in a polymeric material that results in a desired and controlled delivery of a therapeutically effective amount of GnRH agonist over an extended period of time in order to treat central precocious puberty (CPP).

Abstract: The invention relates to a method of treating endometriosis using a combination of an aromatase inhibitor, a progestin and an oestrogen. The invention also relates to pharmaceutical formulations comprising said combination.

Abstract: The invention concerns a concentrated hormone pharmaceutical composition having from about 0.6 to about 80% of at least one hormone; from about 20 to about 90.4% of at least one solvent, and optionally a pharmaceutically acceptable carrier. The concentrated hormone pharmaceutical composition according to this invention provides a concentrated pharmaceutical composition that is easy to use and saves time and money to the pharmacies dealing with BHRT pharmaceutical products.

Abstract: The present invention relates to a microorganism, preferably a bacterial strain, preferably a non-pathogenic strain, preferably a non-invasive strain, preferably a food grade strain, preferably a gram-positive bacterial strain, delivering a trefoil peptide in vivo. Preferably the trefoil peptide is TFF1. The present invention further relates to a method for the delivery of trefoil peptide to the gastro-intestinal tract comprising the administration of such a bacterial strain. The present invention also relates to a pharmaceutical composition comprising a trefoil peptide delivering bacterium as well as methods of treatment of acute gastro-intestinal inflammatory diseases comprising administration of transformed bacterial strains, particularly for treating acute colitis, including but not limited to acute flare-ups of Crohn's disease and ulcerative colitis in humans, as well as for treating gastro-intestinal disorders of a similar nature in other animal species.

Abstract: A method for treating/relief of women's menstruation pain. The pain is reduced or relieved by externally administering an effective amount of an essential oil obtained from anthopogon.

Abstract: Dental products such as toothpastes, mouthwash and dental floss are disclosed which products are enhanced by having dissolved, dispersed or coated thereon a compound which promoted bone growth. Preferred compounds are peptide sequences comprising 10 to 50 amino acids are disclosed. The sequences are characterized by containing an integrin binding motif such as RGD sequence and the remainder of amino acids contiguous with the RGD sequence in matrix extracellular phosphoglycoprotein. The sequences may be formulated for dispersed in toothpaste or a mouthwash and administered to enhance bone/tooth growth. When the dental products are used repeatedly over time they enhance good dental health.

Abstract: A method of using an herbal extract of a mixture of: Herba Scutellaria barbata, Radix Sophora subprostratae, Radix Anemarrhena, Semen Glycine sojae, Radix Glycyrrhiza, Rhizoma Rhei, Fructus Tritici levis, Radix Astragali, Radix Rehmania, Fructus Ligustri lucidi, Semen Zyziphi spinosa, Plumula Nelumbinis, Poria cocos, Rhizoma Alismatis, Cortex Moutan radicis, Fructus Corni, Radix Achyranthis, Concha Ostrea, Radix Aspargi, Radix Pueraria, Radix Atractylodis macrocephala and Herba Epimedium, for the treatment of hot flashes associated with menopause is disclosed herein.

Abstract: Topical analgesics, generally comprising calendula oil and cornmint oil, and methods of use.

Abstract: A soya extract having a content of glucoside isoflavones of at least 13% by weight and a content of 0.6 to 1.5 parts by weight of group 3 soya saponins per 1 part by weight of glucoside isoflavones. Also, pharmaceutical compositions containing this extract and methods of administering the extract to treat conditions such as pre- or post-menopausal symptoms, cancer, such as breast or prostate cancer, or alcoholism. The extracts are made by a process which includes the steps of treating ripe whole soya beans or oil-free soya flour with an aliphatic alcohol to obtain a first extract; concentrating the first extract to form a concentrated first extract; purifying the concentrated first extract by treatment with at least one aliphatic hydrocarbon; and extracting active components from the purified concentrated first extract with a water-immiscible aliphatic alcohol to obtain a second extract. Preferably, the final extract is concentrated dried to form the desired soya extract.

Abstract: The application discloses methods of treating mammalian diseases characterized by abnormal cell mitosis by administering estradiol derivatives including those comprising colchicine or combretastatin A-4 structural motifs of the general formulae found below in a dosage sufficient to inhibit cell mitosis. The application discloses novel compounds used in the methods.

Abstract: The invention relates to pharmaceutical combination preparations with synergistic action for the treatment of migraine. Said preparations contain plant-based components and/or preparations of Tanacetum parthenium in combination with Vitex agnus castus and/or Cimicifuga racemosa and/or Zingiber officinale as their pharmaceutically active ingredients. The combination preparation provided for in the invention is suitable for the treatment of not only the headache but also the other symptoms of migraine while avoiding the usual side-effects.

Abstract: The present invention provides a method for treating psychiatric disorders such as mania or depression in a patients, in particular, patients with a bipolar disorder, by providing substantially isotopically pure heavy water substantially free of protons, isotopically pure hydrogen-containing water substantially free of deuterium, isotopically pure carbonate compounds substantially free of deuterium, isotopically pure carbonate compounds substantially free of protons, isotopically pure phosphate compounds substantially free of deuterium, isotopically pure phosphate compounds substantially free of protons, or mixtures thereof to the patient. In particular, the present invention provides a method for treating manic symptoms in a patient and mania or depression in patients with a bipolar disorder.

Abstract: A local anesthetic is used for the manufacture of a medicament for use against dysmenorrhoea and premenstrual syndrome and for increasing fertility. A pharmaceutical composition may also be used that comprises a pharmaceutically effective dose of a local anesthetic together with a pharmaceutically acceptable excipient. The invention also relates to a process for using a catheter to pertubate the fallopian tubes to reduce dysmenorrhoea and premenstrual syndrome symptoms in a woman with the pharmaceutical composition that is intended to reach and exert an effect in the peritoneal cavity.

Abstract: A local anesthetic is used for the manufacture of a medicament for use against dysmenorrhoea and premenstrual syndrome and for increasing fertility. A pharmaceutical composition may also be used that comprises a pharmaceutically effective dose of a local anesthetic together with a pharmaceutically acceptable excipient. The invention also relates to a process for using a catheter to pertubate the fallopian tubes to reduce dysmenorrhoea and premenstrual syndrome symptoms in a woman with the pharmaceutical composition that is intended to reach and exert an effect in the peritoneal cavity.

Abstract: Formulations have been developed for regional delivery of drugs, for example, into a cavity such as the pelvic region, peritoneal region, or directly on organs of interest. Regional delivery increases comfort and bioavailability of the drug, resulting in rapid and relatively high blood levels in the regions to be treated in the substantial absence of side effects due to the high levels required for efficacy following systemic delivery. In the preferred embodiment, these formulations consist of drug micro or nanoparticles, which may be formed of drug alone or in combination with an excipient or polymeric carrier. The excipient or polymer may be used to manipulate release rates and to increase adhesion to the affected region. The drug formulation can be applied as a dried powder, a liquid suspension or dispersion, or as a topical ointment, creme, lotion, foam or suppository.

Abstract: Topical analgesics, generally comprising calendula oil and cornmint oil, and methods of use.

Abstract: The present invention provides a method for inhibiting activity of TGF-&bgr;, comprising contacting tissue expressing TGF-&bgr; with an amount of ebaf or an ebaf analogue. The present invention further provides a method for treating a condition associated with overactivity of TGF-&bgr;, particularly fibrosis, a defect in cell proliferation, or a coagulation defect. The present invention also provides a method for inhibiting activity of TGF-&bgr;, comprising contacting tissue expressing TGF-&bgr; with a modulator of ebaf expression, or a modulator of expression of an ebaf analogue. The present invention is further directed to a method for treating fibrosis in a subject in need of treatment, comprising administering to the subject an amount of ebaf or an ebaf analogue effective to treat the fibrosis.

Abstract: A method for diagnosis of pre-eclampsia is disclosed, which comprises measuring the hormone inhibin A in a biological sample such as maternal serum. The method allows non-invasive, early diagnosis and can be used to predict the onset of secondary symptoms.

Abstract: The present invention teaches that daily, cyclical vaginal delivery of progestin may be used to provide regular, predictable withdrawal bleeding during hormone replacement therapy. The present invention also teaches that constant administration of progestin in a water-insoluble, water-swellable cross-linked polycarboxylic acid polymer may be used to maintain amenorrhea. Either regimen is accompanied by a significant decrease in adverse side effects.

Abstract: A composition is prepared by extracting phytochemicals from plant matter. This composition is enriched preferably in isoflavones, lignans, saponins, catechins and phenolic acids. Soy is the preferred source of these chemicals; however, other plants may also be used, such as red clover, kudzu, flax, and cocoa. The composition is a dietary supplement for treatment of various cancers, pre- and post-menstrual syndromes, and various other disorders.

Abstract: The present disclosure relates to novel compositions which provide improved nutritional support for premenopausal and menopausal women and/or relief from symptoms associated with menopause, as well as prophylactic effects, and methods for using same.

Abstract: A method of reducing or inhibiting mucositis in a patient, which includes administering an inflammatory cytokine inhibitor or a mast cell inhibitor, or a combination thereof, is disclosed.

Abstract: Competitive progesterone antagonists (antigestagens) are suitable for the production of pharmaceutical agents for the treatment of forms of dysfunctional uterine bleeding (metrorrhagias, menorrhagias, hypermenorrhea).

Abstract: A method of treating symptoms linked to menopause in warm-blooded animals by administering to warm-blooded animals in need thereof an amount of a compound of the formula wherein the substituents are defined as in the application sufficient to treat said symptoms.

Abstract: Formulations have been developed for regional delivery of drugs, for example, into a cavity such as the pelvic region, peritoneal region, or directly on organs of interest. Regional delivery increases comfort and bioavailability of the drug, resulting in rapid and relatively high blood levels in the regions to be treated in the substantial absence of side effects due to the high levels required for efficacy following systemic delivery. In the preferred embodiment, these formulations consist of drug micro or nanoparticles, which may be formed of drug alone or in combination with an excipient or polymeric carrier. The excipient or polymer may be used to manipulate release rates and to increase adhesion to the affected region. The drug formulation can be applied as a dried powder, a liquid suspension or dispersion, or as a topical ointment, creme, lotion, foam or suppository.

Abstract: The present invention discloses a method for treating baterial dental caries caused by Streptococcus mutans, comprising administering a composition comprising an effective amount of at least one lytic enzyme produced by a bacteriophage specific for Streptococcus mutans, with the lytic enzyme having the ability to exclusively digest a cell wall of the Streptococcus mutans infecting all or part of a mouth or teeth, and a toothpaste for delivering the enzyme to the mouth and teeth.

Abstract: A composition is prepared by extracting phytochemicals from plant matter to form a dietary supplement for treatment of female symptoms. This composition is enriched preferably with two or more fractions of plant matter, namely: isoflavones, lignans, saponins, sapogenins, catechins and phenolic acids. Soy is the preferred source of these chemicals; however, other plants may also be used, such as wheat, psyllium, rice, oats, red clover, kudzu, alfalfa, flax, and cocoa. The isoflavone may be any in a group including malonyl, acetyl, glucoside, and aglycone. The composition is in a concentrated form to be delivered in an easy to consume dosage, such as a pill, tablet, liquid, capsule, or a food supplement including health bars. Most commonly, these female symptoms are hot flashes, osteoporosis, sleep disorders, menopausal symptoms, vaginal dryness, premenstrual syndrome, or other problems relating to a reduction of sex hormones and to menstruation.

Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof in which R1 and R2 are independently H or methyl (for example N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) is used for treating menstrual function and infertility.

Abstract: Emollient compositions for topical administration consisting of hydrophilic:hydrophobic emulsions containing a polyacrylate carrier, a vehicle, a mixture of C16:0, C18:0, C18:1 fatty acids and derivatives as penetrants, a balanced mixture of unsaturated C18:2, C18:2 and C18:3 fatty acids, a natural anti-inflammatory compound, a natural analgesic compound, a natural estrogenic compound and a fragrance; Methods of their use for ameliorating symptoms of disease including mammary fibrocystic disease, cyclic mastitis, inflammation and general and specific pre- and post-menopausal pain and swelling.

Abstract: There is described a method for the treatment or prevention of menopausal symptoms or osteoporosis wherein there is administered to a subject in need of such treatment a therapeutically effective amount of the isoflavone formononetin, or a method for the treatment or prevention of menopausal symptoms wherein there is administered to a subject in need of such treatment a therapeutically effective amount of the isoflavone daidzein, the isoflavone being optionally administered with one or more pharmaceutically acceptable adjuvants, carriers and/or excipients. Therapeutic uses and compositions/foods are also described, comprising daidzeii or formononetin optionally in association with one or more pharmaceutically acceptable adjuvants, carriers, food components and/or excipients.

Abstract: This invention provides a method of providing progestational therapy to a mammal in need thereof which comprises administering a progestationally effective amount of a pharmaceutically acceptable salt of 5&agr;-pregnan-3&bgr;-ol-20-one 3-sulfate ester to said mammal.

Abstract: The present invention teaches that daily, cyclical vaginal delivery of progestin may be used to provide regular, predictable withdrawal bleeding during hormone replacement therapy. The present invention also teaches that constant administration of progestin in a water-insoluble, water-swellable cross-linked polycarboxylic acid polymer may be used to maintain amenorrhea. Either regimen is accompanied by a significant decrease in adverse side effects.

Abstract: Methods and articles of manufacture are provided for the long-term prevention of clinical symptoms and signs produced by endometriosis. Such methods and articles of manufacture involve the continuous coadministration of low doses of an estrogen agent and a progestin agent to maintain an induced state of oligomenorrhea or amenorrhea in an afflicted woman.

Abstract: The present invention comprises a selection of herbal, organic and inorganic materials with curative effects combined in a powdered form for human ingestion. The demonstrated benefits on human female hormone regulation or replacement include return from irregular to regular and less painful menstrual cycles, raising estrogen and progesterone levels to normal levels through menstrual cycles, return to regular menstrual cycle hormone levels with apparent infertility cure, and return to normative metabolic response from apparent circulatory abnormalities such as excessive sweating, edema, cold hand and feet, stiffness and other such symptoms.

Abstract: The present invention relates to methods for alleviating disorders or chronic conditions of the female reproductive system, such as dysmenorrhea, endometrial pain, and pre-term labor, through dietary supplementation with histidine. The invention relates further to novel combination supplements of histidine in conjunction with other nutritional supplement materials which are preferably also useful in alleviating the above-mentioned disorders or conditions. A method for administering a dietary histidine supplement in conjunction with one or more separately formulated therapeutic drugs also known to be useful in treating these female reproductive conditions is also disclosed.

Abstract: The present invention relates to methods and compositions for preventing or treating conditions or disorders of the female reproductive system by administering an effective dosage of histidine alone or in combination with other therapeutic agents. The invention relates also to novel physical compositions and delivery devices for administering histidine effectively to a female subject in need of either prophylaxis or treatment of certain disorders of the reproductive system.

Abstract: Methods, compositions, and compounds for modulating the GABA.sub.A receptor-chloride ionophore complex to alleviate stress, anxiety, seizures, mood disorders, PMS and PND and to induce anesthesia.

Abstract: This invention describes the new 17-difluoromethylene-estratrienes of general formula I ##STR1## in which R.sup.1 is a hydrogen atom or a C.sub.1 -C.sub.10 alkyl group,R.sup.5 is a methyl or ethyl group, andR.sup.2 is a hydrogen atom or a C.sub.1 -C.sub.10 alkyl group in .alpha.- or .beta.-position,R.sup.3 is a hydrogen atom or a C.sub.1 -C.sub.10 alkyloxy group in .alpha.- or .beta.-position,R.sup.4 is a hydrogen atom in .alpha.- or .beta.-position, and A, B, D, E and G each is a hydrogen atom, and optionally at least one of substituent pairsG and R.sup.2, R.sup.2 and R.sup.4, R.sup.4 and A, A and R.sup.3, B and D, D and E is a double bond.

Abstract: The present invention relates to dietary supplements containing low doses of phytoestrogens for supplementing the specific phytochemical dietary needs of perimenopausal and menopausal women.

Abstract: An herbal composition is disclosed comprising as active ingredients chickweed, yarrow, wormwood, motherwort, pennyroyal, and dandelion in a vehicle of olive-oil and beeswax. The composition alleviates cramps, aches and pains, such as those associated with premenstrual syndrome.

Abstract: The symptoms of the climacterium are ameliorated by the administration to an afflicted individual one or both of a nitric oxide substrate and/or nitric acid donor, alone or optionally in combination with a progestin or, in the case of a non-pregnant female, either a progestin or an estrogen or both.

Abstract: Methods of detecting and treating rapidly growing exogenous cells, such as Protista, or parasites, that preferentially accumulate a photoactivatable porphyrin in which 5-aminolevulinic acid or precursor thereof is administered to the patient, or contacted to the exogenous cells, in an amount sufficient to induce synthesis fluorescence and/or photosensitizing concentrations of a protoporphyrin IX in the exogenous cells, followed by exposure of the exogenous cells to light of photoactivating wavelengths.

Abstract: This invention relates to an herb composition which comprises an amount of 30 to 45% by weight of one or more herbs for invigorating of blood circulation, an amount of 55 to 70% by weight of one or more herbs for excreting toxin from human body, and an amount of 0.

Abstract: The present invention is concerned with the use of starch containing amylose as a complexant with iodine for preparing dry powder pharmaceutical formulations useful in the preparation of capsules or tablets. The helical structure of the amylose molecule and its ability to complex with smaller molecules including iodine make starch (amylose) a desirable vehicle for the administration of iodine (I.sub.2) as a dry powder formulation in capsule or tablet form. These pharmaceutical formulations are particularly useful in the treatment of or the prevention of iodine deficiency diseases including breast dysplasia, breast cancer, endometriosis, premenstrual syndrome, ovarian cysts and radiation sickness from nuclear fallout.

Abstract: A liquid composition for the relief of discomfort, in particular, premenstrual and menstrual discomfort including, as active pharmaceutical agents, an effective amount of one or more of an analgesic, an antihistamine and a diuretic, said active agents being, or adapted to be, dissolved in a liquid vehicle, said composition preferably containing 5-25 percent by volume alcohol (or other effective liquid carrier such as glycerin, or even water) and being flavored with an active flavoring composition including (1) citrus and mint ingredients, (2) vanilla and mint ingredients, or (3) citrus, vanilla and mint ingredients, said active flavoring ingredients being present in an amount sufficient to mask the unpleasant taste of the pharmaceutically active agent(s).

Abstract: A composition is disclosed for alleviating or managing symptoms associated with premenstrual syndrome “PMS” comprising an effective amount of an aqueous mixture of water and a rapidly digestible carbohydrate blend. The aqueous mixture is essentially free of protein and is characterized by a certain pH and ratio of water to carbohydrate blend. Methods of use of the composition for alleviating or managing symptoms associated with PMS are also disclosed.